Director of the Israel National Haemophilia Centre and Thrombosis Institute, Sheba Medical Centre and Director of Amalia Biron Research Institute of Thrombosis and Haemostasis, Tel Aviv University (located at the Sheba Medical Centre). Gili Kenet is a paediatric haematologist, Professor and former Chair of the Haematology Department at the Sackler Medical School, Tel Aviv University. Professor Kenet received her Medical Degree from the Hebrew University in Jerusalem. Her research projects have been focused on neonatal haemostasis, childhood stroke and paediatric thrombophilia, as well as the research of new therapy modes applied for people with haemophilia and severe bleeding disorders. She was awarded national grants for paediatric haematology and cancer research, study of rFVIIa mode of action, epidemiology of inhibitor evolution in haemophilia and for personalised tailoring of bypass agent therapy, and applying global haemostasis assays. Prof. Kenet pioneered in gene therapy clinical trials in Israel and novel non replacement drugs in haemophilia. Professor Kenet is the author of over 200 peer reviewed scientific publications, review articles and book chapters. An active member of the World Federation of Haemophilia, Israeli Society of Paediatric Haematology and Oncology, and the American Society of Haematology, an active reviewer for high impact thrombosis journals and an editorial board member of the Haemophilia journal. Former Chairperson of the Israeli Society of Thrombosis and Haemostasis and Chairperson of the Paediatric and Peri-natal Haemostasis Scientific Subcommittee of ISTH. Currently co-chairs the FVIII/FIX and rare bleeding disorders of the SSC of ISTH.
Bayer, Biomarin, CSL, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda and Uniquore.